Detrimental weight loss is exacerbated by bridging therapies in chimeric antigen receptor (CAR) T-cell therapy

Rationale: CAR T-cell therapy is revolutionising the treatment of previously incurable cancers; however, our research has identified several associations between poor nutritional status and adverse outcomes, including body weight (BW) loss prior to treatment1. Additional anti-cancer Bridging Therapies (BTs) are commonly used pre-treatment to avoid disease progression during the long CAR T manufacturing process. The aim of this data review was to evaluate the effect of BTs on BW in patients prior to CAR T-cell therapy.

Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: B. Cucchiaro, A. Slee, C.E. Weekes, N.A. Davies Source Type: research